Evidence map›Paper›PMID 28618652›Full record

ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2017

Cross-talk of MicroRNA and hydrogen sulfide: A novel therapeutic approach for bone diseases.

Yuankun Zhai, Suresh C Tyagi, Neetu Tyagi

Open access · greenAbstract readReview
In one paragraph

Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Black gas, bright future: HNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  4. H2S inhibits high glucose-induced osteoblast injury by inhibiting ferroptosis in diabetic osteoporosis in vitro.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Association of Hydrogen Sulfide with Femoral Bone Mineral Density in Osteoporosis Patients: A Preliminary Study.Medical science monitor : international medical journal of experimental and clinical research · 2021
    Article
  10. Article
  11. Review
  12. Article
  13. Genetic susceptibility of postmenopausal osteoporosis on sulfide quinone reductase-like gene.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018
    Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yuankun ZhaiDepartment of Physiology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Suresh C TyagiDepartment of Physiology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Neetu TyagiDepartment of Physiology, School of Medicine, University of Louisville, Louisville, KY 40202, USA. Electronic address: n0tyag01@louisville.edu.
University of Louisville · US

Funding

Mitigating mitochondrial epigenetics in bone remodeling by hydrogen sulfideR01AR067667 · NIAMS · UNIVERSITY OF LOUISVILLE · PI TYAGI, NEETU, TYAGI, SURESH C. · 2015 to 2019
$2.5M
Mechanisms of Mitochondrial Dysfunction in Brain VasculatureR01HL107640 · NHLBI · UNIVERSITY OF LOUISVILLE · PI TYAGI, NEETU · 2012 to 2016
$1.8M
NHLBI NIH HHS R01 HL107640NIAMS NIH HHS R01 AR067667
6 · The paper itself

Abstract

Bone homeostasis requires a balance between the bone formation of osteoblasts and bone resorption of osteoclasts to maintain ideal bone mass and bone quality. An imbalance in bone remodeling processes results in bone metabolic disorders such as osteoporosis. Hydrogen sulfide (H

Indexed as

Bone RemodelingSignal TransductionAnimalsBone and BonesBone DiseasesGene Expression RegulationGenetic TherapyHumansHydrogen SulfideMicroRNAsHydrogen SulfideMicroRNAsBone remodelingHydrogen sulfideOsteoblastOsteoclastOsteoporosis

Identifiers

PMID28618652
PMCPMC5562148
OpenAlexW2623766737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.